This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

H. Käyhty, PhD; J. Eskola, MD; H. Peltola, MD; P-R. Rönnberg, RN; E. Kela, RN; V. Karanko, RN; L. Saarinen, MSc

Am J Dis Child. 1991;145(2):223-227.

Abstract
• Serum antibody responses to four Haemophilus influenzae type b capsular polysaccharide-protein conjugate vaccines (PRP-D, HbOC, C7p, and PRP-T) were studied and compared in 175 infants, 85 adults, and 140 2-year-old children. Antibodies to the H influenzae type b polysaccharide vaccines were determined with a Farr-type radioimmunoassay. The infants received two doses of vaccine at the ages of 4 and 6 months. After the first dose of vaccine, the geometric mean antibody concentration measured at the age of 6 months was 0.09 to 0.10 mg/L, only marginally higher than that measured before immunization in all infants who had received PRP-D, HbOC, or C7p but increased to 0.82 mg/L in those who had received PRP-T. One month after the second dose, the geometric mean antibody concentration was increased in all vaccine groups. No significant differences were noted between recipients of HbOC, C7p, or PRP-T (geometric mean antibody concentrations, 4.32,3.10, and 6.10 mg/L, respectively), whereas the PRP-D recipients had a significantly lower geometric mean antibody concentration (0.63 mg/L). In contrast, PRP-D, HbOC, C7p, and PRP-T were all highly immunogenic in adults, with no differences noted among them. The 2-year-old children also responded to one dose of these vaccines with a high antibody concentration.

(AJDC. 1991;145:223-227)

Author Affiliations
From the Department of Bacteriology, National Public Health Institute, Helsinki, Finland.

Footnotes
Accepted for publication May 30, 1990.

Reprint requests to National Public Health Institute, Manner-heimintie 166, 00300 Helsinki, Finland (Dr Eskola).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phase I Clinical Evaluation of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b in Human Adult Volunteers
Torano et al.
CVI 2006;13:1052-1056.
ABSTRACT | FULL TEXT  

Utility of the Antibody Response to a Conjugated Haemophilus influenzae Type B Vaccine for Diagnosis of Primary Humoral Immunodeficiency
RODRIGO et al.
Am. J. Respir. Crit. Care Med. 2000;162:1462-1465.
ABSTRACT | FULL TEXT  

Are the Enzyme Immunoassays for Antibodies to Pneumococcal Capsular Polysaccharides Serotype Specific?
Soininen et al.
CVI 2000;7:468-476.
ABSTRACT | FULL TEXT